00:00 Cardiovascular manifestations also need to be evaluated. 00:04 We look for rhabdomyomas in the heart in young children. 00:08 Many of those children grow out of that tumor in early infancy, or early childhood, and no further imaging is required. 00:15 EKGs are performed in young adolescents and adults to look for cardiac arrhythmias and blood pressure monitoring is key annually. 00:22 We watch for that lymphangioleiomyomatosis or LAM, that finding we can see in the lungs, and that's monitored in older adults, or adults who have concerning pulmonary findings. 00:35 Renal monitoring and renal assessment is also very important, and can be done with a variety of imaging about every one to three years. 00:42 We look at the skin with a dermatologic exam and the eyes with an ophthalmologic exam, there is a multidisciplinary team that helps to take care of these patients. 00:51 Not something I need you to know all the details about, but I want you to remember the types of things that we look out for in these patients. 00:59 What treatments do we have for tuberous sclerosis? Well, there are a few things that we need to treat. 01:05 We need to treat the SEGAs because they could cause obstructive hydrocephalus. 01:09 The AMLs, those renal tumors, angiomyolipomas can bleed in the kidneys, and we may need to treat those. 01:16 The LAM finding that pulmonary finding that can contribute to difficulty with breathing may need treatment. 01:22 And seizures, we also need to treat. 01:24 We manage those symptomatically in a lot of patients, but one medicine I want you to know about is called Everolimus. 01:31 This is an mTOR inhibitor. 01:33 And you'll remember that loss of the TSC1 and TSC2 gene, the tubulin or hamerton proteins, results in increased cellular levels of mTOR. 01:42 mTOR makes cells grow. 01:45 An Everolimus is an mTOR inhibitor. 01:47 So if mTOR is making the cell grow and you give an Everolimus mTOR inhibitor, the tumors don't grow anymore. 01:53 And it turns out that for all of these indications, SEGAs, AMLs, LAM, and seizures, about 50% of patients will have a radiographic response or a seizure reduction as a result of that treatment. 02:07 So the agent is an mTOR inhibitor. 02:08 That's something I want you to remember with Everolimus. 02:11 It is well tolerated, though there's some things we may need to think about, and about 50% of patients respond. 02:17 And you can see here in the MRI image on the right, a patient who began treatment at the top for the SEGA, this Subependymal giant-cell astrocytoma, and was treated over the course of about a year and a half and we see significant reduction in the size, and less concern for obstructive hydrocephalus in that patient.
The lecture Tuberous Sclerosis: Treatment by Roy Strowd, MD is from the course CNS Tumors.
Which of the following is the treatment of choice for tuberous sclerosis?
5 Stars |
|
5 |
4 Stars |
|
0 |
3 Stars |
|
0 |
2 Stars |
|
0 |
1 Star |
|
0 |